牛牛AI助理已提取核心訊息
On January 22, 2024, Panbela Therapeutics, Inc. received a notice from Nasdaq's Listing Qualifications Department regarding non-compliance with the Minimum Float Requirement following a 1-for-20 reverse stock split on January 18, 2024. The company's common stock is at risk of being delisted from the Nasdaq Capital Market, pending a hearing where Panbela will present its compliance plan. The hearing will address the Minimum Bid Price and Minimum Stockholders’ Equity Requirements, with any delisting action on hold until a decision is made. Panbela's common stock will remain listed until the panel's decision. The company is actively seeking ways to regain compliance with Nasdaq's listing rules. Additionally, Panbela announced that its ASPIRE global clinical trial for the treatment of metastatic pancreatic cancer has surpassed 50% enrollment, with full enrollment expected by Q1 2025 and interim data anticipated by mid-2024. The trial is being conducted across approximately 90 sites worldwide.
On January 22, 2024, Panbela Therapeutics, Inc. received a notice from Nasdaq's Listing Qualifications Department regarding non-compliance with the Minimum Float Requirement following a 1-for-20 reverse stock split on January 18, 2024. The company's common stock is at risk of being delisted from the Nasdaq Capital Market, pending a hearing where Panbela will present its compliance plan. The hearing will address the Minimum Bid Price and Minimum Stockholders’ Equity Requirements, with any delisting action on hold until a decision is made. Panbela's common stock will remain listed until the panel's decision. The company is actively seeking ways to regain compliance with Nasdaq's listing rules. Additionally, Panbela announced that its ASPIRE global clinical trial for the treatment of metastatic pancreatic cancer has surpassed 50% enrollment, with full enrollment expected by Q1 2025 and interim data anticipated by mid-2024. The trial is being conducted across approximately 90 sites worldwide.
2024年1月22日，Panbela Therapeutics, Inc.收到納斯達克上市資格部門的通知，內容涉及在2024年1月18日進行1比20的反向股票拆分後，未遵守最低上市量要求。該公司的普通股有從納斯達克資本市場退市的風險，等待Panbela將介紹其合規計劃的聽證會。聽證會將討論最低出價和最低股東權益要求，在做出決定之前，任何退市行動都將暫停。在小組做出決定之前，Panbela的普通股將繼續上市。該公司正在積極尋找重新遵守納斯達克上市規則的方法。此外，Panbela宣佈，其治療轉移性胰腺癌的ASPIRE全球臨床試驗的入組人數已超過50％，預計到2025年第一季度將有全部入組，中期數據預計將在2024年中期出現。該試驗正在全球約90個地點進行。
2024年1月22日，Panbela Therapeutics, Inc.收到納斯達克上市資格部門的通知，內容涉及在2024年1月18日進行1比20的反向股票拆分後，未遵守最低上市量要求。該公司的普通股有從納斯達克資本市場退市的風險，等待Panbela將介紹其合規計劃的聽證會。聽證會將討論最低出價和最低股東權益要求，在做出決定之前，任何退市行動都將暫停。在小組做出決定之前，Panbela的普通股將繼續上市。該公司正在積極尋找重新遵守納斯達克上市規則的方法。此外，Panbela宣佈，其治療轉移性胰腺癌的ASPIRE全球臨床試驗的入組人數已超過50％，預計到2025年第一季度將有全部入組，中期數據預計將在2024年中期出現。該試驗正在全球約90個地點進行。
有用
沒用